Multiple Myeloma Clinical Trials

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of California San Francisco San Francisco, California, United States

Colorado Blood Cancer Institute Denver, Colorado, United States

Yale University School Of Medicine New Haven, Connecticut, United States

Icahn School of Medicine at Mt. Sinai New York, United States

View all 38 locations

View Trial Details

Recruiting

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

NCT06768489

Conditions: Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +20 more
Locations: Monash Medical Centre Clayton, Australia

St Vincents Hospital Melbourne Fitzroy, Australia

Peter MacCallum Cancer Centre Melbourne, Australia

Calvary Mater Newcastle Hospital Waratah, Australia

View all 16 locations

View Trial Details

Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of California San Francisco San Francisco, California, United States

Moffitt Cancer Center Tampa, Florida, United States

University of Iowa Hospital and Clinics Iowa City, Iowa, United States

Memorial Sloan Kettering Cancer Center New York, United States

View all 20 locations

View Trial Details

Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

NCT07073547

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Research Site Phoenix, Arizona, United States

Research Site Duarte, California, United States

Research Site Denver, Colorado, United States

Research Site Tampa, Florida, United States

View all 13 locations

View Trial Details

Recruiting

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

NCT06052826

Conditions: B-Cell Non-Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +17 more
Locations: City of Hope Medical Center Duarte, California, United States

City of Hope at Irvine Lennar Irvine, California, United States

Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology Winston-Salem, North Carolina, United States

Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology Columbus, Ohio, United States

View Trial Details

Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: UAMS Little Rock, Arkansas, United States

USC Norris Comprehensive Cancer Center Los Angeles, California, United States

University of California San Francisco San Francisco, California, United States

Colorado Blood Cancer Institute Denver, Colorado, United States

View all 150 locations

View Trial Details

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Mayo Clinic Cancer Center-Scottsdale Phoenix, Arizona, United States

City of Hope Duarte, California, United States

University of California San Francisco San Francisco, California, United States

Stanford University Medical Center Stanford, California, United States

View all 50 locations

View Trial Details

Recruiting

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

NCT07665450

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Rambam Med.Center - Hematology Institute Haifa, Israel

Carmel Medical Center Haifa, Israel

Shaare Zedek Medical Center Jerusalem, Israel

Rabin Medical Center Petah Tikva, Israel

View all 19 locations

View Trial Details

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Banner MD Anderson Cancer Center Gilbert, Arizona, United States

University of Arizona Cancer Center Tucson, Arizona, United States

UCSF Fresno Clovis, California, United States

City of Hope Duarte Duarte, California, United States

View all 270 locations

View Trial Details

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Jupiter Medical Center/Anderson Family Cancer Institute Jupiter, Florida, United States

MSK Basking Ridge Basking Ridge, New Jersey, United States

MSK Monmouth Middletown, New Jersey, United States

MSK Bergen Montvale, New Jersey, United States

View all 160 locations

View Trial Details

Multiple Myeloma

Multiple Myeloma trial results

Related conditions